Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1/2 7Phase 1 7Phase 3 6Phase 4 3Phase NA 2Phase EARLY_PHASE1 1

Status

Active not recruiting 3Recruiting 2Completed 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

NET 6Gastrointestinal 6Endocrine 6Lymphoid 1

Conditions

Colorectal Neoplasms 439Stomach Neoplasms 248Carcinoma, Hepatocellular 246Rectal Neoplasms 211Colonic Neoplasms 204Pancreatic Neoplasms 172Esophageal Neoplasms 113Neoplasm Metastasis 75Liver Neoplasms 71Neoplasms 63Esophageal Squamous Cell Carcinoma 63Gastrointestinal Stromal Tumors 36Cholangiocarcinoma 36Gastrointestinal Neoplasms 31Parkinson Disease 4, Autosomal Dominant Lewy Body 25Gallbladder Neoplasms 25Adenocarcinoma Of Esophagus 24Biliary Tract Neoplasms 23Anus Neoplasms 22Adenocarcinoma 21Recurrence 19Bile Duct Neoplasms 19Breast Neoplasms 18Digestive System Neoplasms 17Lung Neoplasms 13Prostatic Neoplasms 12Uterine Cervical Neoplasms 11Carcinoma 11Digestive System Diseases 10Peritoneal Neoplasms 9

Interventions

pasireotide 2Octreotide 2Everolimus 2lutetium Lu 177 dotatate 1lanreotide 1amino-acid, glucose, and electrolyte solution 1Temozolomide 1Sunitinib 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Oxaliplatin 1Leucovorin 1Folfox protocol 1Fluorouracil 1Capecitabine 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Gastro-enteropancreatic neuroendocrine tumor × Gastrointestinal × Clear all
NCT06784752 2026-04-30

NETTER-3

Novartis

Phase 3 Recruiting
240 enrolled
EndocrineGastrointestinalLymphoidNET

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Follicular

NCT05477576 2026-03-30

ACTION-1

RayzeBio, Inc.

Phase 3 Recruiting
338 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03972488 2026-01-21

NETTER-2

Advanced Accelerator Applications

Phase 3 Active not recruiting
226 enrolled 14 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT05050942 2025-11-06

SORENTO

Camurus AB

Phase 3 Active not recruiting
332 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT04919226 2025-09-10

COMPOSE

ITM Solucin GmbH

Phase 3 Active not recruiting
259 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT04852679 2024-10-01

PALACE

Ipsen

Phase 3 Completed
43 enrolled 16 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡